Eissing T., Goulooze S.C., Berg van der P., Noort van M., Ruppert M., Snelder N., Garmann D., Lippert J., Heinig R., Brinker M., Heerspink H.J.L. Pharmacokinetics and pharmacodynamics of finerenone in patients with chronic kidney disease and type 2 diabetes: Insights based on FIGARO-DKD and FIDELIO-DKD. Diabetes, Obesity and Metabolism 2023 [Link to publication].
Noort van M., Ruppert M., Goulooze S.C., Berg van den P., Snelder N., Heerspink H.J., Garmann D., Lippert J., Heinig R., Brinker M., Eissing T. From glomerular filtration rate to renal composite endpoint: an integrated time-to-event analysis of finerenone in phase 3 studies. PAGE 2023 [Link to publication]
Fu Y., Snelder N., Guo T., Graaf van der P.H., Hasselt J.G.C. Evaluation of a Cardiovascular Systems Model for Design and Analysis of Hemodynamic Safety Studies. Pharmaceutics, 2023 [Link to publication].
Willmann S., Keller A.K., Meyer M., van der Mey D., Wirsching G., Zhang Y., Drenth H., Keunecke A., Vendel E. Population pharmacokinetics of riociguat in a pediatric population (aged ≥ 6 years) with pulmonary arterial hypertension. Pediatiric Pulmonology, 2022. [Link to publication].
Willmann S., Ince I, Ahsman M., Coboeken K., Zhang Y., Thelen K., Kubitza D., Zannikos P., Zhou W., Pina L., Post T., Lippert J. Model-informed bridging of rivaroxaban doses for thromboprophylaxis in pediatric patients with congenital heart disease aged 9 years and above. CPT: pharmacometrics & systems pharmacology, p001-011, 2022. [Link to publication].
Fu Y., Guo T., Taghvafard H., Said M.M., Demeester C., Dudal V., Graaf van der P.H., Snelder N., Hasselt van C.J.G. A translational cardiovascular systems model to quantify drug effects on contractility and other hemodynamic variables. PAGE 2022 [Link to publication]
Berg van der P., Ruppert M., Mesic E., Snelder N., Seelmann A., Heinig R., Joseph A., Garmann D., Lippert J., Eissing T. Finerenone Dose-Exposure-Response for the Primary Kidney Outcome in FIDELIO-DKD Phase III: Population Pharmacokinetic and Time-to-Event Analysis. PAGE 2022. [Link to publication]
Fu Y., Taghvafard H., Said M.M., Rossman E.I., Collins T.A., Billiald-Desquand S., Leishman D., Graaf van der P.H., Hasselt van C.J.G., Snelder N. A novel cardiovascular systems model to quantify drugs effects on the inter-relationship between contractility and other hemodynamic variables. CPT Pharmacometrics Syst Pharmacol. 2022;00:1–13. [Link to publication].
Goulooze S.C., Heerspink H.J.L., van Noort M., Snelder N., Brinker M., Lippert J. Dose-Exposure-Response Analysis of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone on UACR and eGFR: An Analysis from FIDELIO-DKD. T. Clin Pharmacokinet. 2022 [Link to publication].
van den Berg P, Ruppert M, Mesic E, Snelder N, Seelmann A, Heinig R, Joseph A, Garmann D, Lippert J, Eissing T. Finerenone Dose-Exposure-Response for the Primary Kidney Outcome in FIDELIO-DKD Phase III: Population Pharmacokinetic and Time-to-Event Analysis. Clin Pharmacokinet. 2021. . [Link to publication]